iStock-972355096.jpg

MULTIPRONGED IMMUNOTHERAPY

FOR ONCOLOGY

 

"The one drug, one therapeutic activity dogma is over. Tackling cancer requires to act on multiple targets simultaneously."

TATUM is leveraging years of expertise in synthetic biology to develop a new class of drugs capable of multitasking immunotherapies. This revolutionary multipronged approach triggers a strong and specific antitumor adaptive immune response for 

unparalleled tumor clearance

iStock-972355096.jpg

WELCOME TO

IMMUNO-ONCOLOGY 2.0

 

Founding team

JF.jpg
linkedin.png

Jean-François is a scientist-entrepreneur at heart. Convinced that synthetic biology will trasnform the pharmaceutical industry, he co-founded TATUM to revolutionize the immuno-oncology field.

Kevin.jpg

Kevin Neil, PhD
Co-Founder & CTO

linkedin.png

Kevin, an exceptional synthetic biologist, turned the radically new technological approach developed by TATUM  into a reality. He is convinced that applying synthetic biology principles to the engineering of drugs holds great promise.

Seb.jpg

Sébastien Rodrigue, PhD
Co-Founder & CSO

linkedin.png

Professor at the Université de Sherbrooke, Sébastien has positioned his laboratory at the forefront of Canadian synthetic biology. His profound desire to have a positive impact on the world led him to imagine the breakthrough technologies.

Advisors

Louise Proulx.jpg
linkedin.png

With 30 years in the pharma industry, Louise has held VP positions in successful companies and was former head of Vertex Pharmaceutical Canada. She also worked in the VC sector at Therillia and Sanderling.

PC.jpg
linkedin.png

Equity research analyst in the pharma sectors, Pierre has worked for several financial institutions (BGC Partners, Bryan, Garnier & Co, ODDO BHF) and participated in the IPO of Moderna. He currently is Director Equity Analyst Healthcare at UBP, Geneva.

L Gagnon.jpg
linkedin.png

Lyne spent 20 years at ProMetic where she was VP R&D and pre-clinical studies. She successfully brought seven drugs to clinical trials and two of them are now approved. She currently is a  consultant in preclinical studies for fibrosis and cancer therapies.

Medical Advisors

Photo kaufman.jpg
linkedin.png

Dr. Kaufman is a leading authority on local tumor immunotherapy. He played a key role in the clinical studies of the anti-PD-L1 Avelumab and the T-VEC oncolytic virus. Dr Kaufman is currently the CEO of Ankyra Therapeutics.

Champiat.jpg
linkedin.png

Dr. Champiat is head of the Inpatient Unit in the Drug Development Department at the Gustave Roussy Cancer Campus. He is a rising star in the intratumoral therapy field and strong beleiver this administration route will revolutionize the treatment of cancers.

Batist.jpg
linkedin.png

Dr. Gerald Batist is director of the Department of Oncology at the Montréal Jewish General Hospital and director of McGill University’s Centre for Translational Research in Cancer. He works on novel therapeutics and made significant contributions to the development of new cancer treatments. 

 

Let's get in touch.

Are you interested in collaborating with us? Feel free to contact us. We are looking forward to hearing from you!

Thank you for contacting us!

Join us to create disruptive drugs!

We are constantly looking for talented individuals who are eager to hack biology and develop next-generation drugs.

If you want to join the team at TATUM, please send your CV and motivation letter at:

Jobs_Email .jpg